Role of bronchoalveolar lavage in evaluating new pulmonary infiltrates on computed tomography in haematology patients with fever unresponsive to broad-spectrum antibiotics
Pulmonary complications are a significant cause of morbidity and mortality in immunocompromised haemato-oncology patients, with invasive fungal infection being one of the commonest. Chest computed tomography (CT) with bronchoalveolar lavage (BAL) for further investigation of new pulmonary changes identified on CT is frequently used to investigate patients with neutropenic fever unresponsive to broad-spectrum antibiotics. However, studies of BAL are conflicting, with diagnostic yields of 15-80 % (Milburn et al., 1987; Saito et al., 1988; Peikert et al., 2005) , whilst its role in diagnosing non-infectious aetiologies is limited. Complication rates approach 15 % in haematology patients and some studies have failed to demonstrate a beneficial impact on patient outcome in response to BAL findings (White et al., 1997; Murray et al., 2001) . The optimum role of BAL in the diagnostic pathway of this high-risk population remains unclear.
We attempted to establish the diagnostic yield, complication rate and impact on therapy and outcome of BAL in neutropenic haematology patients with fever unresponsive to broad-spectrum antibiotics and new pulmonary changes on CT.
Addenbrooke's Hospital is a tertiary referral hospital providing chemotherapy and stem cell transplantation for haematology patients. All haematology inpatients undergoing CT chest for antibiotic-unresponsive neutropenic fever (neutrophil count ,0. Although a large recent study has supported the role of BAL in the assessment of such patients, it did not assess the clinical benefit following BAL or report on complications other than death (Hummel et al., 2008) . It also failed to state the type of antimicrobial agents used in the study, and these may have changed over the 15-year study period. Our data, although limited, suggest than in patients empirically treated with broad-spectrum antibiotic and antifungal therapy, BAL has little value and, in accord with many other studies, is a procedure with a significant complication rate. Whilst this study is limited by its single centre retrospective design, the cohort examined nonetheless represents a typical stem-cell transplant centre with many patients with neutropenia (profound and prolonged) and thrombocytopenia. Another potential criticism of the study is that most patients were sampled in the early risk period for invasive mould infections in haematology patients, which may have missed later cases of fungal disease. We reviewed all microbiology records that grew moulds in the study period to counter this. The diagnostic yield of BAL was low, despite national guidelines being largely followed, and the results only changed treatment for one patient. In addition, three patients developed complications, one potentially life-threatening. BAL did not seem to improve patient outcome or reduce duration of admission.
Our study raises questions about the validity of the widely adopted practice of BAL for neutropenic patients with CT changes and fever unresponsive to broadspectrum antibiotics. Our data suggest that it may be more appropriate to consider either excluding BAL or delaying it until antifungal therapy proved ineffective. Future studies should also explore the possible role of fungal antigen detection techniques in supplanting the need for, or refining the indications for, BAL. 
